Mather Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mather Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-19	Closed	-$2.51K	–	1797
2025 Q1	$2.51K	Buy	+19	New	+$2.37K	﹤0.01%	1539
2024 Q3	–	Sell	-75	Closed	-$5.19K	–	2254
2024 Q2	$5.19K	Hold	75	–	–	﹤0.01%	1608
2024 Q1	$5.37K	Buy	+75	New	+$5.16K	﹤0.01%	1343

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mather Group's ITCI Position: Q2 2025 in Review

Mather Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 19 shares — an estimated $2.51K sold.

Mather Group first reported a position in ITCI in Q1 2024 and held it in 3 quarters. The position peaked at $5.37K in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Mather Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Mather Group sold 19 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.51K.
Mather Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 3 quarters.
Mather Group's Intra-Cellular Therapies Inc. position peaked at $5.37K in Q1 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Mather Group's 13F filing for Q2 2025, filed 15 Jul 2025.